This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Edifoligide, CGT003
Description: E2F Decoy is a nucleic acid therapeutic that binds the E2F transcription factor, preventing it from binding to its natural binding site on DNA and activating a specific program of gene expression. Since E2F activates numerous genes required for blood vessel cell growth and proliferation, E2F Decoy prevents the propagation of abnormal cells that would otherwise contribute to atherosclerosis and graft blockade. Secondarily, E2F Decoy can “arterialize” veins, thus making them more suitable for the delivery of oxygen-rich blood to oxygen-starved tissue.
Deal Structure: In October 2003, Corgentech partnered with Bristol-Myers to develop E2F Decoy. Bristol and Corgentech agreed to jointly develop and commercialize E2F Decoy for the prevention of vein graft failure following coronary artery bypass graft (CABG) and peripheral artery bypass graft surgery. The companies agreed to co-promote E2F Decoy in the U.S., while Bristol agreed to market the drug in the rest of the world.
Bristol-Myers Squibb agreed to develop and commercialize the therapeutic and expects the two companies will split the U.S. profits 50-50, and that Corgentech will receive royalties of 12% to 15% for sales in Europe and Japan.
In August 2009, Anesiva and Arcion Therapeutics announced the signing of a definitive merger agreement.
In December 2009, Anesiva announced that it was unable to satisfy the closing conditions set forth in the Agreement and Plan of Merger with Arcion Therapeutics. Anesiva intends to immediately cease operations and to file a petition for relief...See full deal structure in Biomedtracker
E2F Decoy News
Pink Sheet Bristol CABG Drug Fails Phase III
Pink Sheet Bristol ends Corgentech collaboration
Scrip Scholar Rock Inc.
Additional information available to subscribers only: